Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.


NEO:CYBN - Post by User

Comment by realitycheck00on Nov 19, 2020 1:54pm
92 Views
Post# 31934034

RE:RE:RE:RE:RE:TSX listing would have been better

RE:RE:RE:RE:RE:TSX listing would have been betterYou probbaly missed a few things such as 2nd most funded company in Canada ($55M raised) next to MindMed which gives them the cash for M&A.

Large instituational investorbase from the US some of which are also investors in Compass which you can easily cross reference from their press release and Compass's website which lists them and I am sure these type of investors do not buy pie in the sky companies and have probbaly done some more in depth due dillegence then discovering that a biotech company will need to burn money to expand or that you can see the IP listed on their website.

Not trying to be an A** but im protecting my investment with facts.  This industry is still new and the folks with cash who spend it correctly will prevail and the ones who cant raise enough cash will fall to the waistside.




<< Previous
Bullboard Posts
Next >>